bottom line underweight rate reflect
view see downsid pressur street sale earn
guidanc support thesi reduc sale
forecast follow guidanc earli custom
feedback new nextseq product
new product look neat see enhanc cannib
dynam believ featur set promis nextseq
modul especi compel clinic applic specif
rare undiagnos genet diseas rugd market rugd
one smaller compel opportun ilmn total
address market perhap placement
applic increment see increas cannib
novaseq higher power nextseq reduc
forecast accordingli fwiw coupl academ custom
check nextseq seem disinterest cite lack
util hand analysi modul lack
differenti chip current nextseq
wors expect microarray assumpt critic
ilmn microarray sale guidanc wors
contempl forecast vs prior flat assumpt agre
street view critic stori microarray-
associ sale compris
popseq discuss refocus pophealth appreci
ilmn effort refocu pop discuss long-term
pophealth opportun sequenc deploy routin
part clinic care current over-focu view
correct new distributor china prior note
wrote start new distributor relationship china
fact launch new legal entiti custom
purchas local currenc percept new local
entiti new distributor result mistransl
said continu see high-teen assumpt china
growth aggress inconsist check
reiter underweight continu see ilmn stock
underweight transitori product cycl period host
reason foremost among continu downsid risk
pleas see page rate definit import disclosur
requir analyst certif estimates/forecast
well fargo secur llc seek busi compani
cover research report result investor awar
firm may conflict interest could affect object report
investor consid report singl factor make
compani data secur llc estim reuter
exclud amort acquir intang non-cash interest one-tim item
 iprd write-off comput non-gaap dilut sharecount
exclud amort acquir intang non-cash interest one-tim item
 iprd write-off comput non-gaap dilut sharecount
exclud amort acquir intang non-cash interest one-tim item
 iprd write-off comput non-gaap dilut sharecount
exclud amort acquir intang non-cash interest one-tim item
 iprd write-off comput non-gaap dilut sharecount
compani data secur llc estim reuter
price target nc
price target reflect price-to-earnings ratio earn estim multipl
discount median peer group open-end growth stock healthcar believ
appropri given current growth challeng upsid risk underweight rate includ
limit follow factor first faster larger contribut popul sequenc
program model would provid potenti upsid compar estim well
market see faster adopt diagnost greater forecast rebound china
faster ramp consum growth gener could see investor appetit name
increas could see downsid risk continu pattern downward guidanc revis
investor becom disillus stori
underweight rate reflect view see downsid pressur street sale
earn forecast
san diego california-bas inc develop manufactur market
life scienc tool use genom compani technolog encompass two major type system
microarray next gener sequenc via novaseq hiseq nextseq miseq miniseq
platform half compani revenu come consum use variou
platform follow instrument system servic outsourc sequenc genotyp
servic well servic contract product custom includ genom research center
compani agrigenom compani consum genom compani
